ArticleProstate international2022

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland.

Jian Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.